Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study

REFERENCES

1. 1.↵
   1. Yates M,
   2. Graham K,
   3. Watts RA,
   4. MacGregor AJ

   . The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population. BMC Musculoskelet Disord 2016;17:285.

   OpenUrl
2. 2.↵
   1. Partington RJ,
   2. Muller S,
   3. Helliwell T,
   4. Mallen CD,
   5. Abdul Sultan A

   . Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study. Ann Rheum Dis 2018;77:1750–6.

   OpenUrl
3. 3.↵
   1. Crowson CS,
   2. Matteson EL

   . Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. Semin Arthritis Rheum 2017;47:253–6.

   OpenUrl
4. 4.↵
   1. Branco JC,
   2. Rodrigues AM,
   3. Gouveia N,
   4. Eusebio M,
   5. Ramiro S,
   6. Machado PM,
   7. et al.

   Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: Results from EpiReumaPt -a national health survey. RMD Open 2016;2:e000166.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Buttgereit F,
   2. Dejaco C,
   3. Matteson EL,
   4. Dasgupta B

   . Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 2016;315:2442–58.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Fardet L,
   2. Petersen I,
   3. Nazareth I

   . Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology 2011;50:1982–90.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Duarte C,
   2. Ferreira RJ,
   3. Mackie SL,
   4. Kirwan JR,
   5. Pereira da Silva JA

   . Outcome measures in polymyalgia rheumatica. A systematic review. J Rheumatol 2015;42:2503–11.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Leeb BF,
   2. Bird HA

   . A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 2004;63:1279–83.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Mackie SL,
   2. Hughes R,
   3. Walsh M,
   4. Day J,
   5. Newton M,
   6. Pease C,
   7. et al.

   “An impediment to living life”: Why and how should we measure stiffness in polymyalgia rheumatica? PLoS One 2015;10:e0126758.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Huang A,
    2. Castrejon I

    . Patient-reported outcomes in trials of patients with polymyalgia rheumatica: a systematic literature review. Rheumatol Int 2016;36:897–904.

    OpenUrl
11. 11.↵
    1. Kirwan JR,
    2. Boers M,
    3. Tugwell P

    . Updating the OMERACT filter at OMERACT 11. J Rheumatol 2014;41:975–7.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Tugwell P,
    2. Boers M,
    3. D’Agostino MA,
    4. Beaton D,
    5. Boonen A,
    6. Bingham CO 3rd,
    7. et al.

    Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of “truth”: content, face, and construct validity. J Rheumatol 2014;41:1000–4.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Boers M,
    2. Beaton DE,
    3. Shea BJ,
    4. Maxwell LJ,
    5. Bartlett SJ,
    6. Bingham CO 3rd,
    7. et al.

    OMERACT filter 2.1: elaboration of the conceptual framework for outcome measurement in health intervention studies. J Rheumatol 2019;46:1021–7.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Mackie SL,
    2. Twohig H,
    3. Neill LM,
    4. Harrison E,
    5. Shea B,
    6. Black RJ,
    7. et al.

    The OMERACT core domain set for outcome measures for clinical trials in polymyalgia rheumatica. J Rheumatol 2017;44:1515–21.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Twohig H,
    2. Mitchell C,
    3. Mallen C,
    4. Adebajo A,
    5. Mathers N

    . “I suddenly felt I’d aged”: a qualitative study of patient experiences of polymyalgia rheumatica (PMR). Patient Educ Couns 2015;98:645–50.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Twohig H,
    2. Jones G,
    3. Mackie S,
    4. Mallen C,
    5. Mitchell C

    . Assessment of the face validity, feasibility and utility of a patient-completed questionnaire for polymyalgia rheumatica: a postal survey using the QQ-10 questionnaire. Pilot Feasibility Stud 2017;4:7.

    OpenUrl
17. 17.↵
    1. Hewlett S,
    2. Cockshott Z,
    3. Byron M,
    4. Kitchen K,
    5. Tipler S,
    6. Pope D,
    7. et al.

    Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005;53:697–702.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Castrejon I,
    2. Huang A,
    3. Everakes SL,
    4. Nika A,
    5. Sequeira W

    . Clinical improvement according to RAPID3 in patients with polymyalgia rheumatica: a longitudinal analysis from routine care. J Clin Rheumatol 2018;24:390–2.

    OpenUrl